The Aβcentric Pathway of Alzheimer’s Disease

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-1-84628-440-3_2
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• The molecular pathology of amyloid deposition in Alzheimer's disease

  2008cited by this paper
• Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42.

  2008cited by this paper
• Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer’s disease

  2007cited by this paper
• Effects of lipophilicity on the affinity and nonspecific binding of iodinated benzothiazole derivatives

  2007cited by this paper
• Appendix B: Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the quality standards subcommittee of the American academy neurology

  2007cited by this paper
• Characterization of radioiodinated ligand binding to amyloid β plaques

  2007cited by this paper
• Molecular basis of Alzheimer’s disease

  2007cited by this paper
• Development of a Monoclonal Antibody Specific for @3/A4Amyloid in Alzheimer's Disease Brain for Application to In Vivo Imaging of Amyloid Angiopathy

  2006cited by this paper
• DifferentialDiagnosis of Alzheimer's Disease with PET

  2006cited by this paper
• Genetic factors in the genesis of Alzheimer's disease.

  2006cited by this paper
• The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.

  2006cited by this paper
• Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease

  2006cited by this paper
• Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease.

  2005cited by this paper
• Reduction of lipid peroxidation in different brain regions by a combination of α-tocopherol and ascorbic acid

  2005cited by this paper
• Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging

  2004cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Studies of Aβ Pharmacodynamics in the Brain, Cerebrospinal Fluid, and Plasma in Young (Plaque-Free) Tg2576 Mice Using the γ-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575)

  2004cited by this paper
• Inaugural Article: Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule

  2004cited by this paper
• Selected Non-steroidal Anti-inflammatory Drugs and Their Derivatives Target γ-Secretase at a Novel Site

  2004cited by this paper
• Anti‐Aβ: The good, the bad, and the unforeseen

  2004cited by this paper
• Alzheimer's disease pathogenesis and therapeutic interventions.

  2004cited by this paper
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

  2004cited by this paper
• Experimental excitotoxicity provokes oxidative damage in mice brain and attenuation by extract of Asparagus racemosus

  2004cited by this paper
• Apolipoprotein E protects against oxidative stress in mixed neuronal-glial cell cultures by reducing glutamate toxicity.

  2004cited by this paper
• Lessons from the AN 1792 Alzheimer vaccine: lest we forget.

  2004cited by this paper
• Redox‐Active Metals, Oxidative Stress, and Alzheimer's Disease Pathology

  2004cited by this paper
• Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons.

  2004cited by this paper
• X11α impairs γ‐ but not β‐cleavage of amyloid precursor protein

  2004cited by this paper
• In vivo amyloid imaging in Alzheimer’s disease

  2004cited by this paper
• Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation*

  2004cited by this paper
• Neurodegenerative diseases and oxidative stress

  2004cited by this paper
• Accuracy of early diagnosis and its impact on the management and course of Alzheimer’s disease

  2004cited by this paper
• The γ-Secretase Inhibitor N-[N-(3,5-Difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl Ester Reduces Aβ Levels in Vivo in Plasma and Cerebrospinal Fluid in Young (Plaque-Free) and Aged (Plaque-Bearing) Tg2576 Mice

  2003cited by this paper
• H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK.

  2003cited by this paper
• Structure of the Alzheimer's Disease Amyloid Precursor Protein Copper Binding Domain

  2003cited by this paper
• Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Aβ production in APP23 transgenic mice

  2003cited by this paper
• The metallobiology of Alzheimer's disease.

  2003cited by this paper
• Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.

  2003cited by this paper
• Detection of amyloid plaques by radioligands for Aβ40 and Aβ42

  2003cited by this paper
• Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence.

  2003cited by this paper
• Alzheimer vaccine: amyloid-beta on trial.

  2003cited by this paper
• Neuronal and glial calcium signaling in Alzheimer's disease.

  2003cited by this paper
• The Binding of 2-(4′-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component

  2003cited by this paper
• Vaccines for Alzheimer’s Disease

  2003cited by this paper
• Dementia, 2nd ed.

  2003cited by this paper
• Emerging β-Amyloid Therapies for the Treatment of Alzheimer's Disease

  2003cited by this paper
• In vivo reduction of amyloid-β by a mutant copper transporter

  2003cited by this paper
• Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice

  2003cited by this paper
• Dimethylamino-fluorenes: ligands for detecting β-amyloid plaques in the brain

  2003cited by this paper
• Sulindac Sulfide Is a Noncompetitive γ-Secretase Inhibitor That Preferentially Reduces Aβ42 Generation*

  2003cited by this paper
• A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease.

  2003cited by this paper
• A novel probe for imaging amyloid-β : Synthesis of F-18 labelled BF-108, an Acridine Orange analog

  2003cited by this paper
• Differential Effects of Inhibitors on the γ-Secretase Complex

  2003cited by this paper
• Magnetic Resonance Studies of β-Amyloid Peptides

  2003cited by this paper
• Copper, β-amyloid, and Alzheimer's disease: Tapping a sensitive connection

  2003cited by this paper
• Memantine: update on the current evidence

  2003cited by this paper
• Challenges of targeting A beta fibrillogenesis and other protein folding disorders.

  2003cited by this paper
• 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease.

  2003cited by this paper
• Causative and susceptibility genes for Alzheimer's disease: a review.

  2003cited by this paper
• Amyloid inhibitors and Alzheimer's disease.

  2003cited by this paper
• Treating the full spectrum of dementia with memantine

  2003cited by this paper
• Memantine in moderate-to-severe Alzheimer's disease.

  2003cited by this paper
• Amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β

  2003cited by this paper
• Two novel presenilin-1 mutations (Y256S and Q222H) are associated with early-onset Alzheimer's disease.

  2003cited by this paper
• Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain.

  2003cited by this paper
• Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

  2003cited by this paper
• Metal Ions, pH, and Cholesterol Regulate the Interactions of Alzheimer's Disease Amyloid-β Peptide with Membrane Lipid*

  2003cited by this paper
• Neurotoxic, Redox-competent Alzheimer's β-Amyloid Is Released from Lipid Membrane by Methionine Oxidation*

  2003cited by this paper
• Molecular-Imaging Probe 2-(1-{6-[(2-Fluoroethyl)(Methyl) Amino]-2-Naphthyl}Ethylidene) Malononitrile Labels Prion Plaques In Vitro

  2003cited by this paper
• Neuroimaging and early diagnosis of Alzheimer disease: a look to the future.

  2003cited by this paper
• Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory.

  2003cited by this paper
• Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.

  2003cited by this paper
• Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria

  2003cited by this paper
• Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation

  2003cited by this paper
• In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile.

  2003cited by this paper
• Phenolic antioxidants attenuate hippocampal neuronal cell damage against kainic acid induced excitotoxicity

  2003cited by this paper
• Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment.

  2002cited by this paper
• Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease

  2002cited by this paper
• Lipid peroxidation in neurodegeneration: new insights into Alzheimer's disease

  2002cited by this paper
• Imaging Amyloid-β Deposits In Vivo

  2002cited by this paper
• Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning

  2002cited by this paper
• In vivo brain imaging of tangle burden in humans

  2002cited by this paper
• Imaging Aβ Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy‐X04, a Systemically Administered Congo Red Derivative

  2002cited by this paper
• Alzheimer's disease-do tauists and baptists finally shake hands?

  2002cited by this paper
• Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

  2002cited by this paper
• S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death

  2002cited by this paper
• Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD

  2002cited by this paper
• Advances in the Development of Abeta-Related Therapeutic Strategies for Alzheimer's Disease.

  2002cited by this paper
• Metal complexing agents as therapies for Alzheimer's disease.

  2002cited by this paper
• Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice.

  2002cited by this paper
• Methionine 35 Oxidation Reduces Fibril Assembly of the Amyloid Aβ-(1–42) Peptide of Alzheimer's Disease*

  2002cited by this paper
• Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits.

  2002cited by this paper
• Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis

  2002cited by this paper
• Hydrogen magnetic resonance spectroscopy in Alzheimer's disease.

  2002cited by this paper
• Noninvasive imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo.

  2002cited by this paper
• Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death.

  2002cited by this paper
• Potential neurotoxic inflammatory responses to Aβ vaccination in humans

  2002cited by this paper
• Potential novel targets for Alzheimer pharmacotherapy: I. Secretases

  2002cited by this paper
• Amyloid β peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures

  2002cited by this paper

• Beta-amyloid imaging in dementia

  2018cites this paper
• Rule-based Risk Monitoring Systems for Complex Datasets

  2016cites this paper
• Amyloid-β as a biomarker for Alzheimer’s disease: quantification methods in body fluids

  2015cites this paper
• Efficacy of Multifunctionalized Saccharide Constructs for the Attenuation of Amyloid-beta Toxicity

  2012cites this paper
• Molecular imaging in dementia: journey to the end of the night

  2009cites this paper
• Sialic Acid Conjugated Chitosan for the Attenuation of Amyloid-beta Toxicity

  2009cites this paper
• High Striatal Amyloid (cid:2) -Peptide Deposition Across Different Autosomal Alzheimer Disease Mutation Types

  2009influential citation